An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Trial Status: enrolling by invitation
Multicenter, open-label, prospective treatment protocol that provides continued access to
ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting
from treatment with ibrutinib, and have no access to commercial ibrutinib for their
underlying disease within their region.
Inclusion Criteria
Subject must have participated in an eligible ibrutinib clinical trial, may derive clinical benefit from continued treatment or restart of treatment with ibrutinib in the opinion of the treating physician and does not have access to commercial ibrutinib within their region and/or the drug is not reasonably accessible to the patient within the respective region.
Ongoing continuous treatment with ibrutinib.
Subject must have completed all assessments in their parent protocol and want to continue treatment with ibrutinib.
Subject or their legally authorized representative must voluntarily sign and date an informed consent approved by an independent ethics committee (IEC)/institutional review board (IRB) to the long term treatment extension protocol and not withdrawn consent from the parent study.
Male and female subjects of reproductive potential who agree to use both a highly effective method of birth control and a barrier method during the period of therapy and for 90 days after the last dose of drug.
Exclusion Criteria
Meeting any requirement in the parent protocol to permanently discontinue ibrutinib treatment.
Any condition or situation which, in the opinion of the treating physician, may interfere significantly with a subject's participation in the protocol.
Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while enrolled in this protocol or within 90 days of last dose of drug treatment. Male subjects who plan to father a child while enrolled in this protocol or within 90 days after the last dose of drug treatment.
Unwilling or unable to participate in all required evaluations and procedures.
Unable to understand the purpose and risks of the protocol and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information.
Additional locations may be listed on ClinicalTrials.gov for NCT03229200.
Locations matching your search criteria
United States
California
Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: Active
Name Not Available
North Carolina
Charlotte
Carolinas Medical Center/Levine Cancer Institute
Status: Active
Name Not Available
Pennsylvania
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: Active
Name Not Available
Multicenter, open-label, prospective treatment protocol that provides continued access to
ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting
from treatment with ibrutinib, and have no access to commercial ibrutinib for their
underlying disease within their region.
Subjects enrolled in this treatment protocol will receive oral continuous dosing with
ibrutinib at the same dose and schedule they were receiving at the end of the respective
parent study. Treatment may be continued as long as the subjects continue to derive
benefit from treatment with ibrutinib until such time that ibrutinib becomes commercially
available for the indication of the parent study.
Clinical evaluations (including safety assessments) will be performed per local standard
of care for each disease that was studied in the parent protocol. At each visit, all
ongoing and new onset non-serious AEs leading to dose reduction or discontinuation,
serious adverse events (SAEs), adverse events of special interest (AESI), pregnancy
events, other malignancies, and special reporting situations will be recorded.
